HPS-056 - A comprehensive approach to SGLT2 inhibitors safety: Results from a two-year quality initiative on prescription screening and patient education

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-056
• By: SERMHATTAKIT, Anuchit (ViMUT-Theptarin Hospital, Thailand)
• Co-author(s): Mr Anuchit Sermhattakit (ViMUT-Theptarin Hospital, Bangkok, Thailand)
  
• Abstract:

  Background: SGLT2 Inhibitors (SGLT2i) are highly effective for treating Type 2 diabetes but require careful consideration in patients with low eGFR. Additionally, these medicines carry risks of urinary tract infections (UTI) and genital infections as potential side effects. With the expanding role of SGLT2i in managing cardiovascular and renal..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login